Jasper Therapeutics Future Growth
Future criteria checks 0/6
Jasper Therapeutics's earnings are forecast to decline at 13.9% per annum while its annual revenue is expected to grow at 60.8% per year. EPS is expected to grow by 9.2% per annum.
Key information
-13.9%
Earnings growth rate
9.2%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 60.8% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully
Jan 23
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth
Jul 31We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate
Feb 02Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely
Oct 14Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02
Aug 12Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?
Jun 19Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning
Nov 28We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth
Nov 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -96 | -103 | -91 | 7 |
| 12/31/2025 | 6 | -75 | -78 | -82 | 7 |
| 12/31/2024 | N/A | -71 | -70 | -70 | 7 |
| 12/31/2023 | N/A | -64 | -52 | -52 | N/A |
| 9/30/2023 | N/A | -61 | -48 | -48 | N/A |
| 6/30/2023 | N/A | -55 | -46 | -46 | N/A |
| 3/31/2023 | N/A | -50 | -43 | -42 | N/A |
| 12/31/2022 | N/A | -38 | -46 | -46 | N/A |
| 9/30/2022 | N/A | -34 | -49 | -48 | N/A |
| 6/30/2022 | N/A | -25 | -47 | -45 | N/A |
| 3/31/2022 | N/A | -23 | -43 | -42 | N/A |
| 12/31/2021 | N/A | -31 | -36 | -34 | N/A |
| 9/30/2021 | N/A | -32 | -26 | -24 | N/A |
| 6/30/2021 | N/A | -39 | -27 | -25 | N/A |
| 3/31/2021 | N/A | -40 | -24 | -23 | N/A |
| 12/31/2020 | N/A | -32 | -18 | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JSPR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: JSPR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: JSPR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: JSPR is forecast to have no revenue next year.
High Growth Revenue: JSPR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if JSPR's Return on Equity is forecast to be high in 3 years time